Management of common adverse events in patients treated with Sorafenib: Nurse and pharmacist perspective

Seminars in Oncology

Volumn 41, Issue SUPPL. 2, 2014, Pages

  Walko, Christine M ^a   Grande, Carolyn ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTIHYPERTENSIVE AGENT; ATROPINE PLUS DIPHENOXYLATE; CORTICOSTEROID; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE 1A9; LOPERAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLATELET DERIVED GROWTH FACTOR RECEPTOR; UREA; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVERSE DRUG REACTION; ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FATIGUE; GENERALIZED RASH; HAND FOOT SKIN REACTION; HUMAN; HYPERTENSION; INTERPERSONAL COMMUNICATION; NURSE; PATIENT EDUCATION; PHARMACIST; PRIORITY JOURNAL; RASH; SKIN MANIFESTATION; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BLOOD PRESSURE MONITORING; CANCER CHEMOTHERAPY; DESQUAMATION; DRUG ERUPTION; DRUG GLUCURONIDATION; DRUG INTERACTION; DRUG MECHANISM; DRUG OXIDATION; EARLY DIAGNOSIS; ENERGY CONSERVATION; EXERCISE; HAND FOOT SYNDROME; HYDRATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOADING DRUG DOSE; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; REST; SELF MONITORING; TOPICAL TREATMENT; WEIGHT BEARING;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; DISEASE MANAGEMENT; FATIGUE; GASTROINTESTINAL DISEASES; HAND-FOOT SYNDROME; HUMANS; HYPERTENSION; KIDNEY NEOPLASMS; LIVER NEOPLASMS; NIACINAMIDE; NURSES; PATIENT EDUCATION AS TOPIC; PHARMACISTS; PHENYLUREA COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84896735888     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.01.002     Document Type: Article

References (80)

1. Nexavar (sorafenib) tablets prescribing information. Wayne, NJ; Bayer HealthCare Pharmaceuticals, Inc; 2012.
2. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 2.2014. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp#site. Accessed January 23, 2014.
3. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Hepatobiliary Cancer. Version 2.2013. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#site. Accessed January 23, 2014.
4. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
5. A. Cheng, Y. Kang, Z. Chen, C.-J. Tsao, S. Qin, and J.S. Kim et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: results of a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
6. G.K. Abou-Alfa, D. Amadori, A. Santoro, A. Figer, J. De Greve, and C. Lathia et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis Gastrointest Cancer Res 4 2011 40 44
7. A.A. Miller, D.J. Murry, K. Owzar, D.R. Hollis, E.B. Kennedy, and G. Abou-Alfa et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 J Clin Oncol 27 2009 1800 1805
8. R. Lencioni, M. Kudo, S.L. Ye, J.P. Bronowicki, X.P. Chen, and L. Dagher et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study Int J Clin Pract 66 2012 675 683
9. J. Marrero, R. Lencioni, M. Kudo, S.L. Ye, K. Nakajima, F. Cihon, and A. Venook GIDEON (Global Investigation Of Therapeutic Decisions In Hepatocellular Carcinoma [HCC] And Of Its Treatment With Sorafenib) 2nd interim analysis in more than 1,500 patients: clinical findings in patients with liver dysfunction [abstract] J Clin Oncol (Meeting Abstracts) 29 2011 4001
10. J. Marrero, R. Lencioni, S.L. Ye, M. Kudo, J.P. Bronowicki, and X.P. Chen et al. Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in>3000 Sor-treated patients (pts): clinical findings in pts with liver dysfunction [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 4126
11. A.L. Cheng, Z. Guan, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III sorafenib Asia-Pacific trial Eur J Cancer 48 2012 1452 1465
12. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, and M. Siebels et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 256 2007 125 134
13. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, and M. Staehler et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
14. M. Ahmed, Y. Barbachano, A.M. Riddell, S. Whittaker, K. Newbold, and K. Harrington et al. An open labelled phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer [abstract] Ann Oncol (Meeting Abstracts) 19 2008 691PD
15. M.S. Brose, A.B. Troxel, K. Harlacker, M. Redlinger, A.A. Chalian, and L.A. Loevner et al. Completion of a phase II study of sorafenib for advanced thyroid cancer [abstract] Eur J Cancer (Meeting Abstracts) 7 2009 51LBA
16. R.T. Kloos, M.D. Ringel, M.V. Knopp, N.C. Hall, M. King, R. Stevens, and J. Liang et al. Phase II trial of sorafenib in metastatic thyroid cancer J Clin Oncol 27 2009 1675 1684
17. V. Gupta-Abramson, A.B. Troxel, A. Nellore, K. Puttaswamy, M. Redlinger, and K. Ransone et al. Phase II trial of sorafenib in advanced thyroid cancer J Clin Oncol 26 2008 4714 4719
18. J. Baselga, J.G. Segalla, H. Roché, A. Del Giglio, H. Pinczowski, and E.M. Ciruelos et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer J Clin Oncol 30 2012 1484 1491
19. Clinicaltrials.gov. Identifier: NCT00984282. A double-blind randomized phase III study evaluating the efficacy and safety of sorafenib compared to placebo in locally advanced/metastatic RAI-refractory differentiated thyroid cancer. http://clinicaltrials.gov/ct2/show/NCT00984282. Accessed January 23, 2014.
20. Clinicaltrials.gov. Identifier: NCT01234337. A phase III randomized, double blind, placebo-controlled trial comparing capecitabine plus sorafenib versus capecitabine plus placebo in the treatment of locally advanced or metastatic HER2-negative breast cancer. http://www.clinicaltrials.gov/ct2/show/ NCT01234337. Accessed January 23, 2014.
21. M. Kudo, K. Imanaka, N. Chida, K. Nakachi, W.Y. Tak, and T. Takayama et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma Eur J Cancer 47 2011 2117 2127
22. Zhu AX, Rosmorduc O, Evans J, Ross P, Santoro A, Carrilho FJ, et al. A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC) [poster]. Poster presented at: the European Society for Medical Oncology; 2012 September 28-October 2; Vienna, Austria. Abstract 917.
23. K.T. Flaherty, S.J. Lee, F. Zhao, L.M. Schuchter, L. Flaherty, and R. Kefford et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma J Clin Oncol 31 2013 373 379
24. A. Hauschild, S.S. Agarwala, U. Trefzer, D. Hogg, C. Robert, and P. Hersey et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma J Clin Oncol 27 2009 2823 2830
25. G. Scagliotti, S. Novello, J. von Pawel, M. Reck, J.R. Pereira, and M. Thomas et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer J Clin Oncol 28 2010 1835 1842
26. Paz-Ares L, Hirsh V, Zhang L, De Marinis F, Yang JC, Wakelee H, et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III, randomized, double-blind, placebo-controlled MISSION trial [abstract]. Ann Oncol (Meeting Abstracts). 2012;23:LBA33-PR.
27. L.G. Paz-Ares, B. Biesma, D. Heigener, J. von Pawel, and T. Eisen et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer J Clin Oncol 30 2012 3084 3092
28. A. Gonçalves, M. Gilabert, E. François, L. Dahan, H. Perrier, and R. Lamy et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer Ann Oncol 23 2012 2799 2805
29. S. Bhatia, J. Moon, K.A. Margolin, J.S. Weber, C.D. Lao, and M. Othus et al. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512 PloS One 7 2012 e48787
30. T.J. Herzog, G. Scambia, B.G. Kim, C. Lhommé, J. Markowska, and I. Ray-Coquard et al. A randomized phase II trial of maintenance therapy with sorafenib in front-line ovarian carcinoma Gynecol Oncol 130 2013 25 30
31. J. Tabernero, R. Garcia-Carbonero, J. Cassidy, A. Sobrero, E. Van Cutsem, and C.H. Köhne et al. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial Clin Cancer Res 19 2013 2541 2550
32. Zhou Q, Zhou C-C, Chen G-Y, Chen Y, Huang C, Zhang L, et al. A phase II study of sorafenib monotherapy in the patients with advanced or recurrent non-small-cell lung cancer after failure of EGFR-TKI (CTONG0805) [poster]. Poster presented at the European Society for Medical Oncology; 2012 September 28-October 2; Vienna, Austria. Abstract 1362.
33. Deleporte A, Hendlisz A, Delaunoit T, Marechal R, Peeters M, Holbrechts S, et al. SoMore trial: combining sorafenib (SOR) with capecitabine (CAP) yields highly encouraging survival results and elevated metabolic response rate in chemorefractory metastatic colorectal cancer (mCRC) [poster]. Presented at the European Society for Medical Oncology; 2012 September 28-October 2; Vienna, Austria. Abstract 569.
34. Iressa (gefitinib) tablets prescribing information. Wilmington, DE; AstraZeneca Pharmaceuticals LP; 2010.
35. Sutent (sunitinib) capsules prescribing information. New York, NY; Pfizer Labs; 2012.
36. Tarceva (erlotinib) tablets prescribing information. South San Francisco, CA; Genentech, Inc; 2012.
37. Votrient (pazopanib) tablets prescribing information. Research Triangle Park, NC; GlaxoSmithKline; 2012.
38. Inlyta (axitinib) tablets prescribing information. New York, NY; Pfizer; 2012.
39. W.M. Stadler, R.A. Figlin, D.F. McDermott, J.P. Dutcher, J.J. Knox, and W.H. Miller Jr et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Cancer 116 2010 1272 1280
40. J. Beck, G. Procopio, E. Bajetta, U. Keilholz, S. Negrier, and C. Szczylik et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings Ann Oncol 22 2011 1812 1823
41. R.M. Bukowski, W.M. Stadler, D.F. McDermott, J.P. Dutcher, J.J. Knox, and W.H. Miller Jr et al. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program Oncology 78 2010 340 347
42. L. Zhang, Q. Zhou, L. Ma, Z. Wu, and Y. Wang Meta-analysis of dermatological toxicities associated with sorafenib Clin Exp Dermatol 36 2011 344 350
43. D. Chu, M.E. Lacouture, T. Fillos, and S. Wu Risk of hand-foot skin reaction with sorafenib: a systematic review and metaanalysis Acta Oncol 47 2008 176 186
44. M.E. Lacouture, L.M. Reilly, P. Gerami, and J. Guitart Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib Ann Oncol 19 2008 1955 1961
45. S.M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J.M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 2008 3129 3140
46. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, and H. Rong et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
47. K.T. Flaherty, C. Lathia, R.F. Frye, L. Schuchter, M. Redlinger, M. Rosen, and P.J. O'Dwyer Interaction of sorafenib and CYP isoenzymes in patients with advanced melanoma: a phase I/II PK interaction study Cancer Chemother Pharmacol 68 2011 1111 1118
48. J. Autier, B. Escudier, J. Wechsler, A. Spatz, and C. Robert Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor Arch Dermatol 144 2008 886 892
49. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). US Dept of Health and Human Services, National Institutes of Health, National Cancer Institute. August 9, 2006. Available at: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm. Accessed January 23, 2014.
50. R.H. Huggins, T.M. Kuzel, R.T. Anderson, D.P. West, and M.E. Lacouture Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: impact on quality of life (QoL) [abstract] J Clin Oncol 26 2008 16122
51. M.E. Lacouture, S. Wu, C. Robert, M.B. Atkins, H.H. Kong, and J. Guitart et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib Oncologist 13 2008 1001 1011
52. T.E. Hutson, J. Bellmunt, and C. Porta et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET Eur J Cancer 46 2010 2432 2440
53. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cancer-related fatigue. Version 1.2014. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#supportive. Accessed January 23, 2014.
54. R. Anderson, A. Jatoi, C. Robert, L.S. Wood, K.N. Keating, and M.E. Lacouture Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs) Oncologist 14 2009 291 302
55. Z. Ren, K. Zhu, H. Kang, M. Lu, Z. Qu, and L. Lu et al. A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma [abstract] J Clin Oncol 30 2012 4008
56. Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ. Design of RESILIENCE: a phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC) [abstract]. J Clin Oncol (Meeting Abstracts). 2011;29:TPS124.
57. E. Manchen, C. Robert, and C. Porta Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse J Support Oncol 9 2011 13 23
58. H.E. Vonkeman, R.W. Fernandes, J. van der Palen, E.N. van Roon, and M.A. van de Laar Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study Arthritis Res Ther 9 2007 R52
59. M. Hermansson, A. Ekedahl, J. Ranstam, and T. Zilling Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002 BMC Gastroenterol 9 2009 25
60. B. Seruga, H.K. Gan, and J.J. Knox Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer Curr Oncol 16 Suppl 1 2009 S52 S59
61. C. Robert, C. Mateus, A. Spatz, J. Wechsler, and B. Escudier Dermatologic symptoms associated with the multikinase inhibitor sorafenib J Am Acad Dermatol 60 2009 299 305
62. R. Pérez-Soler, J.P. Delord, and A. Halpern et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum Oncologist 10 2005 345 356
63. A.B. Benson 3rd, J.A. Ajani, R.B. Catalano, C. Engelking, S.M. Kornblau, and J.A. Martenson Jr et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea J Clin Oncol 22 2004 2918 2926
64. National Cancer Institute. Nutrition in Cancer Care (PDQ): diarrhea. October 24, 2013. http://www.cancer.gov/cancertopics/pdq/supportivecare/ nutrition/HealthProfessional/page4#Section-148. Accessed January 23, 2014.
65. J.A. Maroun, L.B. Anthony, N. Blais, R. Burkes, S.D. Dowden, and G. Dranitsaris et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea Curr Oncol 14 2007 13 20
66. L.S. Wood Managing the side effects of sorafenib and sunitinib Comm Oncol 3 2006 3 7
67. National Cancer Institute. Gastrointestinal complications (PDQ): diarrhea. September 10, 2013. http://www.cancer.gov/cancertopics/pdq/ supportivecare/gastrointestinalcomplications/HealthProfessional/page5. Accessed January 23, 2014.
68. J. Bellmunt, T. Eisen, M. Fishman, and D. Quinn Experience with sorafenib and adverse event management Crit Rev Oncol Hematol 78 2011 24 32
69. A. Pascual López, M. Roqué i Figuls, G. Urrútia Cuchi, E.G. Berenstein, B. Almenar Pasies, and M. Balcells Alegre et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome J Pain Symptom Manage 27 2004 360 369
70. JNC7. National Heart, Lung, and Blood. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 2004. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full. htm. Accessed January 23, 2014.
71. B. Nazer, B.D. Humphreys, and J. Moslehi Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension Circulation 124 2011 1687 1691
72. S. Miura, M. Fujino, Y. Matsuo, H. Tanigawa, and K. Saku Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway Hypertens Res 28 2005 147 153
73. M.J. Ratain, T. Eisen, and W.M. Stadler et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 205 212
74. S. Kornblau, A.L. Benson III, R. Catalano, R.E. Champlin, C. Engelking, and M. Field et al. Management of cancer treatment-related diarrhea: issues and therapeutic strategies J Pain Symptom Manag 19 2000 118 129
75. Codeine Sulfate USP for oral use, CII prescribing information. Columbus, OH; Roxane Laboratories, Inc; 2013
76. Lyrica (pregabalin) capsules, CV prescribing information. New York, NY; Pfizer Inc; 2013
77. Ibuprofen tablets prescribing information. Allegan, MI; Perrigo Pharmaceuticals Company; 2005
78. Lomotil Cv (diphenoxylate hydrochloride and atropine sulfate tablets, USP) tablets prescribing information. New York, NY; Pfizer Inc; 2005
79. L.S. Wood, and B. Manchen Sorafenib: a promising new targeted therapy for renal cell carcinoma Clin J Oncol Nurs 11 2007 649 656
80. Opium Tincture, USP (deodorized) prescribing information. Whippany, NJ; Halo Pharmaceutical, Inc; 2010